Open dataset · Monthly and after detected source changes
GLP-1 Headline-to-Recurring Price Gap
This view isolates the price jump a buyer can miss when the first number shown is promotional or excludes an ongoing fee.
Key findings from FormBlends Research
FormBlends Research finding 1
#10 of 25 captured offers disclose enough public information to calculate both an introductory amount and recurring all-in amount.
FormBlends Research finding 2
#The largest calculable jump is $349 per month between the public introductory amount and high end of recurring all-in cost.
The data
| Provider | Offer | Intro USD | Recurring low | Recurring high | Gap low | Gap high | Source |
|---|---|---|---|---|---|---|---|
| Ro | Wegovy pen | 199 | 423 | 548 | 224 | 349 | Ro |
| Ro | Zepbound | 299 | 473 | 598 | 174 | 299 | Ro |
| Hims | Wegovy pill | 149 | 298 | 298 | 149 | 149 | Hims |
| Hims | Zepbound | 299 | 448 | 448 | 149 | 149 | Hims |
| Noom Med | Microdose GLP-1 | 49 | 179 | 179 | 130 | 130 | Noom |
| Noom Med | Standard GLP-1 | 129 | 249 | 249 | 120 | 120 | Noom |
| Noom Med | GLP-1 Plus | 149 | 299 | 299 | 150 | 150 | Noom |
| Eden | Compounded semaglutide | 138 | 198 | 198 | 60 | 60 | Eden |
| Eden | Compounded tirzepatide | 238 | 298 | 298 | 60 | 60 | Eden |
| LillyDirect | Zepbound | 299 | 299 | 449 | 0 | 150 | Eli Lilly |
Methodology
- 1. Start with offers where both an introductory amount and recurring all-in amount are established.
- 2. Subtract the introductory amount from both ends of the recurring range.
- 3. Exclude offers rather than infer a gap when either side is unknown.
Limits
- • These are derived measurements from public offer pages, not patient quotes, clinical ratings, or endorsements.
- • Null means the cited page did not establish the field; it does not mean zero.
- • Checkout-only terms, eligibility, state, pharmacy, dose, taxes, and promotions can change the patient-specific amount.